核酶1通过促进T细胞激活来增强对乳腺癌的抗瘤免疫力
Ying-Nai Wang1, Heng-Huan Lee1,2, Zhou Jiang1
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
International journal of biological sciences
|July 7, 2023
概括
人类核糖核酶1 (RNase1) 通过增强适应性免疫力来抑制乳腺癌. RNase1促进抗瘤免疫细胞和T细胞激活,抑制瘤进展并提供一种新的免疫疗法策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 人类核糖核酶1 (RNase1) 是一种分泌酶,在先天免疫,宿主防御和抗癌作用中具有已知的作用.
- 它对瘤微环境 (TME) 内的适应性免疫反应的具体贡献仍然在很大程度上未被探索.
研究的目的:
- 在乳腺癌的背景下调查RNase1在适应性免疫反应中的作用.
- 确定RNase1表达是否影响瘤微环境并影响乳腺癌中的瘤进展.
主要方法:
- 建立一个对乳腺癌与子宫外RNase1表达的综合性免疫能力小鼠模型.
- 质量细胞测量分析,以评估瘤内的免疫学概况.
- 对T细胞激活标记物 (CD69) 和杀死癌症潜力的分析.
- 对RNase1与EGFR-CD3双特异抗体结合的评估.
主要成果:
- 宫外RNase1表达在小鼠模型中显著抑制了乳腺癌的进展.
- 在TME中,RNase1诱导的CD4+T辅助1 (Th1) 和T辅助17 (Th17) 细胞,自然杀手细胞,以及减少的粒细胞髓衍生的抑制细胞.
- RNase1增强了T细胞介导的抗瘤免疫力,其证据是CD4+T细胞子集上的CD69表达增加.
- 结合RNase1和EGFR-CD3双特异性抗体的联合治疗表明对乳腺癌细胞有保护作用.
结论:
- 通过调节TME内的自适应性免疫反应,RNase1在乳腺癌中表现出抑制瘤的作用.
- RNase1促进抗瘤TME,并增强T细胞介导的免疫力.
- 将RNase1与现有的癌症免疫疗法结合起来,为免疫能力强的乳腺癌患者提供了潜在的治疗策略.
相关概念视频
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
The Nucleolus
8.9K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K


